<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02886572</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00075429</org_study_id>
    <nct_id>NCT02886572</nct_id>
  </id_info>
  <brief_title>SIMT Stereotactic Radiosurgery Outcomes Study</brief_title>
  <acronym>SIMT</acronym>
  <official_title>Outcome in Patients With 4 or More Brain Metastases Treated With Single-Isocenter, Multi-Target (SIMT) Stereotactic Radiosurgery: A Prospective Single-arm Study in Adults With Brain Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Varian Medical Systems</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effectiveness and efficiency of Single&#xD;
      Isocenter Multi-target Stereotactic Radiosurgery (SIMT SRS) in patients with four or more&#xD;
      brain metastases&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Forty patients with four or more brain metastases will be enrolled prior to radiosurgery. A&#xD;
      planning MRI brain scan will be performed with GD-DPTA within one week prior to radiosurgery,&#xD;
      per the standard of care. Neurocognitive (Mini-Mental Status Examination (MMSE), Trail-making&#xD;
      test A&amp;B, Hopkins Learning Verbal (HVLT)) and functional assessment of cancer therapy-brain&#xD;
      (FACT- Br) will be obtained prior to radiosurgery. Dose will be prescribed to the maximum&#xD;
      isodose line encompassing the resulting PTV using the dose guidelines as described below.&#xD;
&#xD;
      The primary endpoint will be the proportion of patients who live longer than predicted based&#xD;
      on the diagnosis-specific GPA score. The Kaplan-Meier estimator will be used to describe the&#xD;
      survival of all patients treated with SIMT SRS. Secondary endpoints will be the rate of&#xD;
      recurrence at the treated metastases sites, the rate of new brain metastases at a site&#xD;
      different from the SRS-treated metastases sites, the rate of death due to neurological&#xD;
      causes, and the prevalence of significant adverse events. Exploratory endpoints include&#xD;
      change over time in neurocognition and quality of life, quantification of dosimetric&#xD;
      measures, the rate of salvage therapy, the rate of radionecrosis at the SRS treatment sites,&#xD;
      and the rate and intensity of steroid-usage post-SRS.&#xD;
&#xD;
      All patients will be evaluated for neurocognitive function via MMSE, HVLT, and Trail-making&#xD;
      tests A &amp; B, quality of life via FACT-Br, and for local recurrence via MRI every 3 months&#xD;
      over the course of the study. These evaluations will be done at regular follow-up evaluations&#xD;
      or when local recurrence is suspected on the basis of symptoms. Distant recurrence is defined&#xD;
      as the appearance of new brain metastases at a site different from that of the original&#xD;
      metastases. Recurrence will further be defined as a new area of enhancement that measures&#xD;
      greater than 5 millimeters in the axial plane on MRI. The length of time to recurrence of the&#xD;
      original brain metastases will be calculated from the date of the brain metastases&#xD;
      radiosurgery to the date that a recurrence was detected by MRI. Patients with suspected&#xD;
      recurrent tumor and/or who are symptomatic may undergo a stereotactic biopsy to evaluate for&#xD;
      radionecrosis versus recurrent brain metastases, as is standard of care.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 12, 2017</start_date>
  <completion_date type="Actual">April 30, 2021</completion_date>
  <primary_completion_date type="Actual">April 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients who live longer than predicted according to the Graded Prognostic Assessment (GPA) score</measure>
    <time_frame>Up to 24 months after SRS</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients that experience local brain recurrence within 1 year of SIMT SRS treatment.</measure>
    <time_frame>Up to 12 months after SRS</time_frame>
    <description>Serial MRI's</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who are dead within 1 year of SIMT SRS treatment due to neurologic reasons</measure>
    <time_frame>Up to 12 months after SRS</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients that experience a new brain metastasis at a site different from the original brain metastasis site 1 year after SIMT SRS treatment</measure>
    <time_frame>Up to 12 months after SRS</time_frame>
    <description>Serial MRI's</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who experience grade 3, 4, or 5 neurologic adverse events attributable to SIMT SRS</measure>
    <time_frame>Up to 12 months after SRS</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Brain Metastases, Adult</condition>
  <arm_group>
    <arm_group_label>Stereotactic Radiosurgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will receive stereotactic radiosurgery(SRS) following the RTOG Stereotactic Radiotherapy Guidelines available at http://dx.doi.org/10.1016/j.prro.2011.06.014</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic radiosurgery</intervention_name>
    <description>Linear-accelerator-based, single-isocenter, image-guided stereotactic radiosurgery</description>
    <arm_group_label>Stereotactic Radiosurgery</arm_group_label>
    <other_name>SRS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. A contrast-enhanced MRI scan showing = or &gt; 4 brain metastases.&#xD;
&#xD;
          2. Age &gt;/=18 years of age.&#xD;
&#xD;
          3. KPS &gt;/= 70&#xD;
&#xD;
          4. Patient must have a graded prosnostic score (GPA) score 0.5 or greater&#xD;
&#xD;
          5. Life expectancy of at least 3 months&#xD;
&#xD;
          6. Postoperative patients with resected brain metastases are eligible.&#xD;
&#xD;
          7. Largest lesion &lt; 4cm diameter&#xD;
&#xD;
          8. Must be a candidate for MRI imaging&#xD;
&#xD;
          9. Previous cranial stereotactic radiosurgery (SRS) or whole brain radiation therapy&#xD;
             (WBRT) is allowed if &gt; 3 months prior to SIMT&#xD;
&#xD;
         10. Must be capable of providing informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Primary lesion with radiosensitive histology (i.e., small cell carcinoma, germ-cell&#xD;
             tumors, lymphoma, leukemia, and multiple myeloma).&#xD;
&#xD;
          2. Metastases within 2 mm of the optic apparatus&#xD;
&#xD;
          3. Patients unable to obtain MRI&#xD;
&#xD;
          4. Evidence of leptomeningeal disease&#xD;
&#xD;
          5. Greater than 10 brain metastases&#xD;
&#xD;
          6. Pregnant women are excluded&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Grace J. Kim, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University Medical Center, Radiation Onoclogy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 29, 2016</study_first_submitted>
  <study_first_submitted_qc>August 31, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2016</study_first_posted>
  <last_update_submitted>August 4, 2021</last_update_submitted>
  <last_update_submitted_qc>August 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

